[1] Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy:now and future Antivir Ther,2009,14:13-22. [2] Ahn SH,Kweon YO,Paik SW,et al. Telbivudine in combinatine with adefovir versus adefovir monotherapy in HBeAg-positive,lamivudine-resistant chronic hepatitis B. Hepatol Int,2011,12:448-451. [3] 伍思国,李耀才,杨智娟,等. 拉米夫定抗乙肝转移因子和强肝胶囊治疗慢性乙型肝炎的疗效观察. 实用肝脏病杂志,2006,9(2):84-86. [4] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89. [5] 斯崇文. 对当前慢性乙型肝炎抗病毒治疗的看法. 中华传染病杂志,2005,23(2):73-74. [6] Liaw YF,Leung N,Kao JH, et al. Asian-pacific consensus statement on the management of chronic haepatitis B:a 2008 update. Liver Int,2008,2(3):263-283. [7] Zoulim F,Buti M,Lok AS. Antiviral-resistant heaptitis B virus:Can we prevent the monster from growing. J Viral Hepat,2007,14(supp 1):S29-36. [8] 朱宝剑. 阿德福韦酯联合拉米夫定治疗拉米夫定耐药慢性乙型肝炎患者的临床研究. 中国医师进修杂志,2010,33:22-24. [9] Seifer M,Hamatake RK,Colonno RJ,et al. ln vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother,1998,42:3200-3208. [10] Sherman M,Yurdayin C,Sollano J,et al Entecavir for treatment of lamivudine-refractory,HBeAg-positive chronic hepatitis B. Gastroenterology,2006,130:2039. |